bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evaluation of The Effect of Fisetin against Cyclophosphamide-Induced Myelosuppression and Oxidative Stress in Male Albino Rats
Authors: Jabbar Amani , Alshawi Nada Naji 
Published: October 2023

Myelosuppression is a serious disease that is related to the malfunction of blood cells production that leads to cytopenia which is the most serious hematologic toxicity of cancer chemotherapies including cyclophosphamide, which is a strong oxazaphosphorine [a nitrogen mustard alkylating agent] that can be used alone or combined with other chemotherapeutic agents for the treatment of different malignant diseases. It induces severe bone marrow suppression by damaging hematopoietic stem cells through the generation of oxidative stress. Fisetin is a hydrophobic polyphenolic compound with a wide range of pharmacological properties such as antioxidant, anti-inflammatory, antimicrobial, osteoprotective, antidiabetic, and anti-carcinogenic activities. The present study aims to evaluate the effects of fisetin alone and pretreatment with cyclophosphamide on some selected hematological and oxidative stress parameters in the male rats model. Animals were randomly divided into 4 groups each with 7 rats. The first group received 1% dimethyl sulfoxide (negative control group). The second group received oral fisetin. The third group received a single intraperitoneal (IP) injection of cyclophosphamide (CP) and the fourth group received fisetin for 7 constitutive days than a single IP injection of CP on day 7. Results showed that both fisetin and CP significantly reduced the total white blood cells and platelet counts compared to such counts in negative control/Group I (P<0.05) when each administered alone and in combination. Furthermore, results viewed that fisetin significantly increased GSH and SOD1, and decrease MDA levels in serum compared to such levels in CP (Group III) rats (P<0.05). The study concluded that the administration of fisetin alone causes leukopenia and thrombocytopenia and this decrease augmented in combination with CP; while exhibiting a strong antioxidant effect against CP induced-oxidative stress.
Comparative Study for Citrus Fruits Phytochemical Screening and In-vitro Antioxidant Activity
Authors: AL-KHALIFA IHAB IBRAHIM , Rand A. Aziz  , Mohammed K.Abbas  , Mohammed M. Fadhil  
Published: October 2023

Oxidative stress is one of pharmacological & toxicology mechanisms as an important pathological mechanism proposed for many diseases including cancer . Plant components that include antioxidant components are becoming more popular as an alternative to synthetic antioxidants because of their ability to eliminate free-radical intermediates and prevent further oxidation, Citrus genus, which belongs to the Rutaceae family, comprises among of the world's most frequently harvested crops due to its many nutritional and health advantages.
The preliminary phytochemical analysis of the prepared extract shown the presence of several constituents of citrus peels as Alkaloids, Phenolics , Flavonoids and rutin. Moreover , The result of in-vitro antioxidants activity of both citrus species showed that DPPH radical scavenging activity for peel extract demonstrate dose-dependent inhibition with IC50 was calculated (287.32 ug/ml and 341.89 µg/ml) for pomelo & orange respectively compared to IC50 value of vitamin C which was 260.06 µg/ml as standard antioxidant . in conclusion , study results showed that pomelo peel show higher antioxidant activity compared to orange moreover, citrus peel has significant antioxidant qualities and is a potentially rich source of natural antioxidants, and PPE scavenges DPPH and reactive oxygen radicals very effectively.
Efficacy and Safety of Thymoquinone on Suppression of Tumor Growth in N-butyl-N-(4-hydroxybutyl)-Nitrosamine -Induced Bladder Cancer in Rats
Authors: Salih Hamaamin Qadir Karmand , Marouf Bushra Hassan 
Published: October 2023

Bladder cancer is one of the most common genitourinary malignancies worldwide, the therapeutic approaches for suppression of urothelial tumor and progression toward distant metastasis are not convincing. The present study was conducted to explore the curative effect and safety of THQ in N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced bladder cancer in rat.
Twenty-two male Wister albino rats were allocated into three group G1; served as control (n=6) received only the vehicle. G2: carcinogen group (n=6); animals had 0.05% BBN in drinking water for nine weeks. G3: Treatment group (n=10); THQ was administered at a dose of 50mg/Kg/day orally one week prior to the last exposure of BBN and continued till week 20. The bladder wall of all the animals was examined macroscopically for assessment of the number and the surface area of the lesions using Image J software program. Histopathological evaluation was also done for abnormal morphological alterations. Serum was analyzed for measurement of total oxidant status (TOS) and nuclear factor kappa- κB (NF-κB), transforming growth factor beta-1 (TGF-β1) as well as vascular endothelial growth factor (VEGF). Safety of THQ in respect of hematological, liver and renal function were also investigated. Bladder lesions in the THQ-treated group was reduced versus the carcinogen group. Histopathological findings in THQ-treated group demonstrated a significant improvement in the abnormal morphological growth in bladder, the TOS, NF-kβ, TGF-β, VEGF were mitigated non-significantly in the treatment group. The safety profile of THQ showed no significant deleterious effect on hematological, liver and renal function parameters with no signs of toxicity. THQ inhibited the development of neoplastic, preneoplastic transformations and it suppressed premalignant and malignant lesion formation in a rat model of bladder cancer. This might be due to antioxidant and anti-inflammatory properties of THQ. These data suggested that THQ may be effective and safe in ameliorating urinary bladder carcinogenesis.
Evaluation of Anti-inflammatory Effects of Cinnamic Acid Against Dextran Sodium Sulfate Induced Ulcerative Colitis in Male Mice
Authors: Habboby Maysam , Munaf Hashim Abdulrazzaq  
Published: October 2023

Inflammatory bowel disease (IBD) is a common chronic inflammatory disease of the gastrointestinal tract, including ulcerative colitis and Crohn's disease. ulcerative colitis (UC) disease is characterized by chronic, persistent, recurrent, and nonspecific intestinal ulcers and mucosal inflammation. This study investigated the protective effects of cinnamic acid on dextran sodium sulfate (DSS) induced ulcerative colitis in mice. Forty adult male mice were collected and randomly divided into five groups, group Ӏ received a suspension of distill water and poloxamer, and group ӀӀ received 3% DSS in drinking water for 7 consecutive days. Two treatment groups received an oral suspension of cinnamic acid 50 and 25 mg/kg respectively and 3% DSS in drinking water, for 7 consecutive days and the final group received an oral suspension of cinnamic acid 50mg/kg for 7 days without DSS in drinking water. after All the animals were euthanized on day eight. The sample was collected for analysis. DSS with cinnamic acid 50 mg/kg group revealed a significant (p<0.05) reduction in Tumor necrosis factor α, interleukin 6, nuclear factor-κB ,cinnamic acid 25mg/kg revealed a significant (p<0.05) reduction in Tumor necrosis factor α and nuclear factor-κB but not significant (p>0.05)reduction in IL-6 when compared to the model group. Histopathological examination showed a significant reduction of inflammatory signs in all cinnamic acid-treated groups when compared to the DSS model group.
In conclusion, the treatment with cinnamic acid significantly decreased the levels of DSS-associated oxidative stress. This finding supports the idea that the use of this substance could be used as a potential therapy for patients with ulcerative colitis.
Genetic Polymorphism in TNF-α Promoter Region: Its Association with Severity and Susceptibility to Rheumatoid Arthritis in Iraqi Patients with Active Disease
Authors: Abdulameer Khalid abdulhussein , Hashim Zainab 
Published: October 2023

Objectives: To study the prevalence of rs1799964 (-1031 T/C) and rs361525 (- 238 G/A) SNPs and their effect on the disease activity, severity, and cytokines production in newly diagnosed Iraqi rheumatoid arthritis patients.
Patients and Methods: sixty-three patients were diagnosed by a specialist physician while attending the rheumatology unit and twenty control participated. The inflammatory markers were measured and PCR amplification and sequencing were performed to demonstrate TNF-α SNPs.
Results: Regarding (-1031 C/T) SNP, the TT genotype and allele C were significantly present in the controls, and the CT genotype was distributed significantly in the patients. The TT genotype was mostly distributed in the mild-moderate group, while the CT genotype and allele C were significantly distributed in the severe group. DAS28, TNF-α, IL-1, and ACPA were significantly associated with this SNP. While non-significant differences appeared in the analysis of -238 G/A SNP.
Conclusion: The presence of the CT genotype and C allele of) -1031 C/T( was associated with susceptibility to RA. While the CT genotype and C allele were associated with more severe disease. Also, TT genotype was associated with less severe disease. Furthermore, an association between -1031 C/T and the inflammatory markers and DAS28 was reported.
Structure of Assets and Liabilities of Non-financial Corporations by Selected NACE Sections
Authors: Zawadzka Agnieszka , Szmit Kornelia 
Published: October 2023

Experience from nations with established market economies demonstrates that small and medium-sized businesses are more inventive and able to respond to client demands and needs more quickly than giant businesses. Many publications produced by the EU institutions emphasize their crucial function. Small- and medium-sized enterprises (SMEs) reflect a society's entrepreneurial spirit and a sign of healthy competition in every economy. However, these businesses have numerous growth constraints in a setting that is changing quickly. At first, it is not simple. Due to the higher risk that start-ups face compared to larger corporations, they have difficulty obtaining funding from traditional sources and SME enterprises experience an equity gap. As a result, having access to finance has become crucial to expanding and competing in a particular market. In accordance with the accepted legal norms, the receiver is required to comply with the conditions set forth by the capital donor-recipient to be able to access external sources.
One of the most significant influences on a company's ability to fulfil current obligations in full and generate adequate financial results is adherence to the fundamentals of asset financing, which highlight, among other things, the structural relationships in a company's balance sheet. The purpose of the analysis presented in this text is to identify differences in the structure of assets and liabilities between selected NACE sections of non-financial corporations in 2021 year. All analysed assets and liabilities are characterized by very strong asymmetry. Therefore, the outlier effect has been standardized using Weber median. Further statistical analyses used Kruskal-Wallis non-parametric ANOVA test to determine the similarity between assets and liabilities of selected NACE sections. The analysis showed that there are no significant differences in the assets and liabilities of the different NACE sections.
The PROFIT analysis allowed for a graphical representation of the structure of the similarities between the NACE sections analysed and their arrangement due to the intensity of the assets and liabilities. As regards the NACE sections analysed, three homogeneous groups can be distinguished, of which industry and trade constitute two of them and the others - the third. It has been shown that the industry section is characterized by the highest intensity in both assets and liabilities.
To use or not to use antithrombotics in unruptured cerebrovascular malformations? A systematic review focusing on this clinical and surgical dilemma
Authors: Bianconi Andrea , Ceraudo Marco , Nico Elsa , Minardi Massimiliano , Allevi Mario , Prior Alessandro , Garbossa Diego , Zona Gianluigi , Fiaschi Pietro 
Published: October 2023

OBJECTIVE
Antithrombotic medications (ATMs), including antiplatelet therapy (APT) and oral anticoagulants (OACs), are widely used in current clinical practice for the prevention and treatment of a variety of cardiovascular diseases, deep vein thrombosis, and pulmonary thromboembolisms. The long-term usage of these drugs, associated with an inherent risk of bleeding, raises concerns for unruptured cerebrovascular malformations (UCVMs), such as arteriovenous malformations (AVMs), cerebral cavernous malformations (CCMs), and intracranial aneurysms (IAs), in which the bleeding risk also poses a major threat. The aim of this study was to assess the safety and risk-benefit ratio of ATMs in these various neurosurgical diseases and to give neurosurgeons a safe and reasonable choice regarding whether to administer ATMs to these patients during the course of the disease.

METHODS
The authors conducted a systematic review of the literature (PubMed/MEDLINE and Embase) according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines, which yielded 4 papers about CCMs, 2 about AVMs, and 9 about IAs. The risk of bias was assessed using the Cochrane Collaboration’s tool.

RESULTS
For AVMs, only 2 studies with a total of only 14 patients were included. Data on AVMs and ATMs are limited and weak, relying on small case series. Nevertheless, there is no evidence for either an increased risk of intracranial hemorrhage in patients with AVMs who are receiving ATMS or the need to interrupt ATMs in those patients who have been diagnosed with sporadic, unruptured brain AVMs. With respect to CCMs, the literature search resulted in 4 cohort studies and 1 meta-analysis. These studies affirmed the absence of a correlation between ATMs and an increased risk of CCM bleeding while simultaneously suggesting a protective role of ATMs against bleeding. Concerning IAs, the topic is more complex and debated, despite larger case series on IAs than on AVMs or CCMs. The benefits of ATMs for IAs may vary according to the type of intervention and specific drug administered. Evidence supports the continuation of long-term APT for all patients newly diagnosed with an IA, whereas starting APT in patients with incidentally discovered IA as a means of prophylaxis against rupture is unclear.

CONCLUSIONS
The findings of this review should be taken as a wide overview of UCVM and ATM. Future research should consider the relationship of AVM, CCM, and IA with APT and OAC independently.
Association of tirofiban with improvement of functional outcomes of direct thrombectomy for acute anterior circulation occlusion: a retrospective, nonrandomized, multicenter, real-world study
Authors: Guan *Qiaochu , Yun Wenwei , Li Xiaobo , Ni Huanyu , Lv Weiping , Xie Ziyi , Zhang Lu , Zhou Junshan , Xu Yun , Li Jingwei , Zhang Qingxiu 
Published: October 2023

OBJECTIVE
Although tirofiban and endovascular thrombectomy have been widely used in the treatment of acute ischemic stroke (AIS) patients, the effectiveness of their combined application remains a subject of debate. This study aimed to assess the efficacy and safety of tirofiban in direct thrombectomy for AIS with anterior circulation vessel occlusion.

METHODS
A total of 204 patients undergoing direct thrombectomy between January 2020 and December 2021 for AIS with anterior circulation vessel occlusion from four hospitals were included in this study. Patients at high risk of reocclusion with severe atherosclerosis, those who achieved successful recanalization for ≥ 3 stent retriever passes, or those who underwent emergency stenting or balloon angioplasty for severe residual stenosis were treated with tirofiban. Following a low-dose intra-arterial bolus (0.25–1 mg) immediately after endovascular treatment, tirofiban was administered continuously through intravenous infusion (0.1 μg/kg/min) for 12–24 hours. The primary efficacy outcome was evaluated using the 90-day modified Rankin Scale score. The safety outcome was assessed using symptomatic intracerebral hemorrhage (sICH) and mortality rates.

RESULTS
The tirofiban group and nontirofiban group each included 102 patients. The favorable outcome rate in the tirofiban group was significantly higher than that in the nontirofiban group (53.9% vs 35.3%, p = 0.007). However, the sICH and 90-day mortality rates were lower in the tirofiban group, despite a lack of statistical significance (sICH: 15.7% vs 16.7%, p = 0.849; 90-day mortality: 16.67% vs 24.51%, p = 0.166). Finally, it was found that older patients (> 72 years), male patients, patients with admission National Institutes of Health Stroke Scale scores > 14, patients with a time from onset to reperfusion > 327 minutes, and patients with a medical history of diabetes tend to benefit from tirofiban treatment.

CONCLUSIONS
This study suggests that tirofiban combined with direct thrombectomy improves functional outcomes of AIS and reduces the 90-day mortality rate. Therefore, it could be considered as a suitable treatment option for AIS patients with anterior circulation vessel occlusion.
Effect of perioperative anticoagulant prophylaxis in patients with traumatic subdural hematoma and a history of anticoagulant use: a propensity-matched National Trauma Data Bank analysis
Authors: Jiang Sam H. , Hukamdad Mishaal , Gould Andrew , Bhaskara Mounika , Chiu Ryan G. , Sadeh Morteza , Mehta Ankit I. 
Published: October 2023

OBJECTIVE
The use of anticoagulation to prevent venous thromboembolism (VTE) is controversial in the setting of neurosurgical decompression for traumatic subdural hematoma (SDH). In these patients, there is concern that anticoagulation may cause secondary hemorrhage, increasing the risk of death and other complications. Patients with a history of anticoagulant use are at further risk of VTE, but the effect of VTE prophylaxis (VTEP) following neurosurgery for SDH has not been thoroughly investigated in this population. This study aims to investigate the differences in in-hospital outcomes in patients with SDH and preexisting anticoagulant use who received VTEP following neurosurgical intervention compared with those who did not.

METHODS
The National Trauma Data Bank was queried from 2017 to 2019 for all patients with preexisting anticoagulant use presenting with an SDH who subsequently underwent neurosurgical intervention. Patients who received VTEP were propensity score matched with patients who did not based on demographics, insurance type, injury severity, and comorbidities. Paired Student t-tests, Pearson’s chi-square tests, and Benjamini-Hochberg multiple comparisons correction were used to compare differences in in-hospital complications, length of stay (LOS), and mortality rate between the two groups. A logistic regression model was developed to identify risk factors for in-hospital mortality.

RESULTS
Two thousand seven hundred ninety-four patients matching the inclusion criteria were identified, of whom 950 received VTEP. Following one-to-one matching and multiple comparisons correction, the VTEP group had a lower mortality rate (18.53% vs 34.53%, p < 0.001) but longer LOS (14.09 vs 8.57 days, p < 0.001) and higher rates of pressure ulcers (2.11% vs 0.53%, p = 0.01), unplanned intensive care unit admission (9.05% vs 3.47%, p < 0.001), and unplanned intubation (9.47% vs 6.11%, p = 0.021). The multivariable logistic regression showed that use of unfractionated heparin (UH; OR 0.36, p < 0.001) and low-molecular-weight heparin (LMWH; OR 0.3, p < 0.001) were associated with lower odds of in-hospital mortality.

CONCLUSIONS
In patients with traumatic SDH and a history of anticoagulant use, perioperative VTEP was associated with increased LOS but provided a mortality benefit. LMWH and UH use were the strongest predictors of survival.
Perioperative continuation or ultra-early resumption of antithrombotics in elective neurosurgical cranial procedures
Authors: Rychen Jonathan , Weiger Valentin F. , Halbeisen Florian S. , Ebel Florian , Ullmann Muriel , Mariani Luigi , Guzman Raphael , Soleman Jehuda 
Published: October 2023

OBJECTIVE
Discontinuation of antithrombotics (AT) prior to elective cranial procedures is common practice, despite the higher risk of thromboembolic complications in these patients. The aim of this study was to investigate the risks and benefits of a new perioperative management protocol of continuation or ultra-early AT resumption in elective cranial procedures.

METHODS
This study was an analysis of a prospectively collected cohort of patients undergoing elective cranial surgery with (AT group) and without (control group) AT. For extraaxial or shunt surgeries, acetylsalicylic acid (ASA) was continued perioperatively. For intraaxial pathologies, ASA was discontinued 2 days before surgery and resumed on postoperative day 3. All other AT were discontinued according to their pharmacokinetics, and resumed on postoperative day 3 after unremarkable postoperative imaging. Additionally, the authors performed a retrospective analysis of patients with AT who underwent surgery before implementation of this new AT management protocol (historical AT group). Primary and secondary outcomes were the incidence of hemorrhagic and thromboembolic complications within 3 months after surgery.

RESULTS
Outcomes of 312 patients were analyzed (83 [27%] in the AT group, 106 [34%] in the control group, and 123 [39%] in the historical AT group). For all 3 patient groups, the most common type of surgery was craniotomy for intraaxial tumors (14 [17%] in the AT group, 28 [26%] in the control group, and 60 [49%] in the historical AT group). The most commonly used AT were ASA (38 [46%] in the AT group and 78 [63%] in the historical AT group), followed by non–vitamin K oral anticoagulants (32 [39%] in the AT group and 18 [15%] in the historical AT group). The total perioperative discontinuation time in the AT group was significantly shorter than in the historical AT group (median of 4 vs 16 days; p < 0.001). The rate of hemorrhagic complications was 4% (95% CI 1–10) (n = 3/83) in the AT group, 6% (95% CI 2–12) (n = 6/106) in the control group, and 7% (95% CI 3–13) (n = 9/123) in the historical AT group (p = 0.5). The rate of thromboembolic complications was 5% (95% CI 1–12) (n = 4/82) in the AT group, 8% (95% CI 3–15) (n = 8/104) in the control group, and 7% (95% CI 3–13) (n = 8/120) in the historical AT group (p = 0.7).

CONCLUSIONS
The presented perioperative management protocol of continuation or ultra-early resumption of AT in elective cranial procedures does not seem to increase the hemorrhagic risk. Moreover, it appears to potentially protect patients from thromboembolic complications.